Cyteir Therapeutics Inc

Healthcare US CYT

3.01USD
-0.01(0.33%)

Last update at 2024-04-12T13:30:00Z

Day Range

3.013.01

LowHigh

52 Week Range

1.373.14

LowHigh

Fundamentals

Previous Close 3.02
Market Cap109.79M
Volume0
P/E Ratio-
Dividend Yield-%
EBITDA-33.41500M
Revenue TTM0.00000M
Revenue Per Share TTM-
Gross Profit TTM -16.59100M
Diluted EPS TTM-0.93

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Type	yearly	yearly	yearly	yearly
Date	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Income before tax	-46.06100M	-42.12600M	-20.82300M	-15.04400M
Minority interest	-	-	-	-
Net income	-43.95200M	-41.64700M	-20.82300M	-15.04400M
Selling general administrative	13.55M	11.30M	4.18M	3.35M
Selling and marketing expenses	-	-	-	-
Gross profit	-	-	-	-
Reconciled depreciation	0.67M	0.48M	0.35M	0.21M
Ebit	-48.83800M	-42.73800M	-20.94300M	-16.10500M
Ebitda	-48.17000M	-42.25900M	-20.59200M	-15.89000M
Depreciation and amortization	0.67M	0.48M	0.35M	0.21M
Non operating income net other	2.11M	0.13M	-	-
Operating income	-48.17000M	-42.25900M	-20.94300M	-16.10500M
Other operating expenses	48.17M	42.26M	20.94M	16.11M
Interest expense	0.67M	0.48M	0.00000M	0.00000M
Tax provision	-	-	-	-
Interest income	-	-	-	-
Net interest income	-	-	-	-
Extraordinary items	-	-	-	-
Non recurring	-	-	-	-
Other items	-	-	-	-
Income tax expense	-2.10900M	-0.47900M	-0.12000M	-1.06100M
Total revenue	0.00000M	0.00000M	0.00000M	0.00000M
Total operating expenses	48.17M	42.26M	20.94M	16.11M
Cost of revenue	-	-	-	-
Total other income expense net	2.11M	0.13M	0.12M	1.06M
Discontinued operations	-	-	-	-
Net income from continuing ops	-46.06100M	-42.12600M	-20.82300M	-15.04400M
Net income applicable to common shares	-46.06100M	-42.12600M	-20.82300M	-15.04400M
Preferred stock and other adjustments	-	-	-	-

Breakdown	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Type	yearly	yearly	yearly	yearly
Date	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Total assets	153.23M	195.39M	13.73M	31.37M
Intangible assets	-	-	-	-
Earning assets	-	-	-	-
Other current assets	2.09M	3.35M	1.13M	0.00100M
Total liab	6.95M	8.10M	61.77M	59.70M
Total stockholder equity	146.29M	187.29M	-48.03100M	-28.33600M
Deferred long term liab	-	0.38M	0.06M	-
Other current liab	3.30M	5.73M	1.45M	1.37M
Common stock	0.04M	0.04M	0.00200M	0.00100M
Capital stock	0.04M	0.04M	0.00200M	0.00100M
Retained earnings	-138.11400M	-92.05300M	-49.92700M	-29.10400M
Other liab	-	0.58M	1.22M	0.32M
Good will	-	-	-	-
Other assets	-	0.26M	0.32M	0.14M
Cash	147.12M	189.72M	10.94M	29.01M
Cash and equivalents	-	-	-	-
Total current liabilities	5.32M	7.51M	3.14M	1.97M
Current deferred revenue	-	-	-	-
Net debt	-146.23100M	-189.72300M	-10.93800M	-29.01200M
Short term debt	0.89M	-	-	-
Short long term debt	-	-	-	-
Short long term debt total	0.89M	-	-	-
Other stockholder equity	284.37M	279.31M	1.89M	0.77M
Property plant equipment	1.70M	2.06M	1.29M	0.79M
Total current assets	149.21M	193.08M	12.13M	30.44M
Long term investments	-	-	-	-
Net tangible assets	146.29M	187.29M	-48.03100M	-28.33600M
Short term investments	-	-	-	-
Net receivables	-	0.04M	0.06M	0.16M
Long term debt	-	-	-	-
Inventory	-	-0.03800M	-	1.26M
Accounts payable	1.13M	1.78M	1.69M	0.60M
Total permanent equity	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-
Accumulated other comprehensive income	-	-195.38800M	-	-
Additional paid in capital	-	-	-	-
Common stock total equity	0.04M	0.04M	0.00200M	0.00100M
Preferred stock total equity	-	-	-	-
Retained earnings total equity	-138.11400M	-92.05300M	-	-
Treasury stock	-	-	-	-
Accumulated amortization	-	-	-	-
Non currrent assets other	2.32M	0.26M	0.32M	0.14M
Deferred long term asset charges	-	-	-	-
Non current assets total	4.02M	2.31M	1.60M	0.93M
Capital lease obligations	0.89M	-	-	-
Long term debt total	-	-	-	-

Breakdown	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Type	yearly	yearly	yearly	yearly
Date	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Investments	-0.31200M	-1.18900M	-0.85000M	-0.13300M
Change to liabilities	-3.71700M	4.32M	1.03M	-0.88400M
Total cashflows from investing activities	-0.31200M	-1.18900M	-0.85000M	-0.13300M
Net borrowings	-	-	-	-
Total cash from financing activities	0.24M	216.01M	1.43M	36.89M
Change to operating activities	-1.87100M	2.11M	0.44M	-1.27600M
Net income	-46.06100M	-42.12600M	-20.82300M	-15.04400M
Change in cash	-42.60200M	178.78M	-17.96200M	19.20M
Begin period cash flow	189.98M	11.19M	29.16M	9.96M
End period cash flow	147.38M	189.98M	11.19M	29.16M
Total cash from operating activities	-42.53200M	-36.03200M	-18.53900M	-17.55700M
Issuance of capital stock	0.00000M	215.78M	0.00000M	36.62M
Depreciation	0.67M	0.48M	0.35M	0.21M
Other cashflows from investing activities	-	-	-	-
Dividends paid	-	-	-	-
Change to inventory	-	-	-	-
Change to account receivables	-	-	-	-
Sale purchase of stock	0.24M	216.01M	-	-
Other cashflows from financing activities	0.18M	79.89M	-0.85000M	-0.13300M
Change to netincome	4.68M	3.46M	0.47M	-0.56800M
Capital expenditures	0.31M	1.19M	0.85M	0.13M
Change receivables	-	-	-	-
Cash flows other operating	1.90M	-2.16800M	-	-
Exchange rate changes	-	-	-	-
Cash and cash equivalents changes	-42.60200M	178.78M	-	-
Change in working capital	-2.52800M	2.15M	1.47M	-2.16000M
Stock based compensation	4.68M	3.46M	0.47M	0.25M
Other non cash items	0.71M	10.96M	20.94M	-0.81500M
Free cash flow	-42.84400M	-37.22100M	-19.38900M	-17.69000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to EBITDA (x)
CYT Cyteir Therapeutics Inc	-0.01 0.33%	3.01	-	-	-	0.89	0.41
NVO Novo Nordisk A/S	0.94 2.04%	46.81	41.58	31.15	2.13	32.99	2.11	4.70
NONOF Novo Nordisk A/S	- -%	45.00	41.06	31.25	2.08	33.11	2.11	4.70
VRTX Vertex Pharmaceuticals Inc	2.93 0.63%	469.72	29.67	24.33	10.38	5.83	9.33	20.00
REGN Regeneron Pharmaceuticals Inc	5.28 0.86%	617.77	29.07	20.12	7.57	3.82	6.95	19.42

Reports Covered

View All

Profile

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Cyteir Therapeutics Inc

128 Spring Street, Lexington, MA, United States, 02421

857 285 4140
https://cyteir.com
Employees : 46

Key Executives

Name	Title	Year Born
Mr. Joseph S. Zakrzewski	Independent Investor & Independent Chairman	1962
Dr. Markus F. Renschler M.D.	Pres, CEO & Director	1961
Mr. Timothy Romberger	Independent Director	1972
Dr. Paul Secrist Ph.D.	Chief Scientific Officer	1966
Mr. Andrew W. Gengos	Chief Bus. Officer & Sec.	1964
Dr. Kevin Mills Ph.D.	Co-Founder	NA
Mr. David G. Gaiero	VP of Fin.	1979
Ms. Lisa A. Hayes	VP of Investor Relations & Corp. Communications	NA
Mr. Adam M. Veness Esq.	Gen. Counsel	1986
Ms. Gale Cohen	VP of HR	NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.